Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $42.60 Average Target Price from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given an average recommendation of “Moderate Buy” by the five brokerages that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $42.60.

Several research analysts recently commented on COLL shares. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Piper Sandler reissued a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. HC Wainwright upped their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, Truist Financial boosted their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th.

Insiders Place Their Bets

In related news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is owned by insiders.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. lifted its stake in Collegium Pharmaceutical by 31.8% during the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after purchasing an additional 821,541 shares in the last quarter. Rubric Capital Management LP increased its stake in Collegium Pharmaceutical by 27.2% during the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after purchasing an additional 499,473 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Collegium Pharmaceutical by 411.1% in the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after purchasing an additional 291,286 shares during the period. LSV Asset Management lifted its holdings in Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock worth $14,773,000 after buying an additional 248,751 shares in the last quarter. Finally, Emerald Advisers LLC grew its stake in shares of Collegium Pharmaceutical by 27.2% in the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after acquiring an additional 177,129 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $33.46 on Wednesday. The company has a fifty day moving average of $37.56 and a two-hundred day moving average of $35.28. Collegium Pharmaceutical has a fifty-two week low of $21.40 and a fifty-two week high of $42.29. The stock has a market capitalization of $1.08 billion, a PE ratio of 12.97 and a beta of 0.94. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The firm had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. During the same period last year, the company posted $1.13 EPS. Collegium Pharmaceutical’s quarterly revenue was up 7.2% compared to the same quarter last year. As a group, research analysts forecast that Collegium Pharmaceutical will post 5.81 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.